IG. after-hours. IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the second quarter ended June 30, 2012.
Second Quarter 2012 Highlights vs. 2011
Total revenues of $2.4 million for Q2 2012, an increase of 20% over same quarter in 2011 Total year to date revenues of $4.3 million, an increase of 19% over the same period in 2011 In Q2 2012, IGI submitted three additional abbreviated new drug applications (ANDAs) to the US FDA, bringing the company’s total number of submissions to eight Gross margins improved to 31% in Q2 2012 as compared to 25% in Q1 2012, and were unchanged from Q2 2011 Gross margins year to date improved to 29% in 2012 as compared to 27% in 2011 Net loss was reduced by $0.4 million to $0.6 million in Q2 2012 as compared to $1.0 million in the same quarter in 2011 Net loss per share was $0.01 per share in the second quarter of 2012 as compared to $0.02 in 2011 Net loss included research and development costs of $0.6 million and $0.8 million in 2012 and 2011 http://finance.yahoo.com/news/igi-laboratories-announces-2nd-quarter-200000372.html
News 
Market Data 
Discover 
AI
